Related Experiment Videos
Centrally mediated hyperglycemia by 6-aminonicotinamide
Journal of Nutritional Science and Vitaminology
|January 1, 1978
Summary
6-aminonicotinamide (6-AN) causes hyperglycemia and alters brain/liver glycogen in mice. Adrenalectomy or hexamethonium partially blocks these metabolic changes, indicating a role for the adrenal system.
Area of Science:
- Biochemistry
- Neuroscience
- Endocrinology
Background:
- 6-aminonicotinamide (6-AN) is a known metabolic inhibitor.
- Understanding its effects on glucose metabolism and the adrenal system is crucial.
Purpose of the Study:
- To investigate the metabolic alterations induced by intraventricular 6-AN administration in mice.
- To elucidate the role of the adrenal system in mediating these effects.
Main Methods:
- Intraventricular administration of 6-AN (5-10 µg/animal) to mice.
- Measurement of blood glucose, liver and brain glycogen levels.
- Assessment of adrenal epinephrine content.
- Use of adrenalectomy and hexamethonium to block specific pathways.
Main Results:
- 6-AN induced hyperglycemia, decreased liver and brain glycogen, and reduced adrenal epinephrine.
- Adrenalectomy and hexamethonium prevented hyperglycemia and liver glycogen decrease, but not brain glycogen decrease.
- Hexamethonium reversed the decrease in adrenal epinephrine.
- 6-AN pretreatment reduced insulin toxicity but not its hypoglycemic effect.
Conclusions:
- Intraventricular 6-AN triggers significant metabolic disturbances, including hyperglycemia and altered glycogen stores.
- The adrenal system plays a key role in mediating 6-AN's effects on glucose homeostasis and epinephrine levels.
- Brain glycogen metabolism is affected independently of the adrenal system.